Best longevity and strongest results usually come from a series of 3 sessions (every 46 weeks) plus maintenance
Risks and Considerations While online access to weight loss medications provides convenience, it carries risks
News provided by Eli Lilly and Company Jun 06, 2026, 14:30 ET In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity In addition to weight loss, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) and moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour (60.6%) In TRANSCEND-T2D-1, participants on retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.8%) at 40 weeks, with up to 46% achieving a normal A1C INDIANAPOLIS, June 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced additional positive results from pivotal Phase 3 trials of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, showing substantial weight loss along with meaningful improvements across knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes common obesity-related conditions
[5] GLP-1 agonist market in the UK and Europe In the UK, the GLP-1 receptor agonist market reached a revenue of $847 million USD in 2024, with an expected revenue of $2.2 billion by 2030 and a CAGR of 16% between 2025 and 2030
